Tags

Type your tag names separated by a space and hit enter

Primed for global coronavirus pandemic: Emerging research and clinical outcome.
Eur J Med Chem. 2021 Jan 01; 209:112862.EJ

Abstract

The global effort to combat and contain the coronavirus disease 2019 (COVID-19) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now proceeding on a war footing. The world was slow to react to the developing crisis, but once the contours of the impending calamity became evident, the different state and non-state actors have raced to put their act together. The COVID-19 pandemic has blatantly exposed the shortcomings of our healthcare system and the limitations of medical science, despite considerable advances in recent years. To effectively tackle the current pandemic, almost unprecedented in the modern age, there is an urgent need for a concerted, sustained, and coordinated effort towards the development of new diagnostics, therapeutic and vaccines, and the ramping up of the healthcare infrastructure, especially in the poorer underprivileged nations. Towards this end, researchers around the world are working tirelessly to develop new diagnostics, vaccines, and therapeutics. Efforts to develop a vaccine against COVID-19 are presently underway in several countries around the world, but a new vaccine is expected only by the end of the year-at the earliest. New drug development against COVID-19 and its approval may take even longer. Under such circumstances, drug repurposing has emerged as a realistic and effective strategy to counter the current menace, and several antiviral and antimalarial medicines are currently in different stages of clinical trials. Researchers are also experimenting with nutrients, vitamins, monoclonal antibodies, and convalescent plasma as immunity boosters against the SARS-CoV-2. This report presents a critical analysis of the global clinical trial landscape for COVID-19 with an emphasis on the therapeutic agents and vaccines currently being tested at pandemic speed.

Authors+Show Affiliations

Department of Chemistry, Aligarh Muslim University, Aligarh, 202002, UP, India.Vikor Scientific Biotechnology, Department of Drug Research and Development, 22 WestEdge, Suite 806, Charleston, SC, 29403, USA.Vikor Scientific Biotechnology, Department of Drug Research and Development, 22 WestEdge, Suite 806, Charleston, SC, 29403, USA.Department of Chemistry, Govt. Raza P.G. College, Rampur, 244901, UP, India. Electronic address: mkhcdri@gmail.com.Department of Chemistry, University of Allahabad, Allahabad, 211002, UP, India. Electronic address: saquibem@gmail.com.Vikor Scientific Biotechnology, Department of Drug Research and Development, 22 WestEdge, Suite 806, Charleston, SC, 29403, USA. Electronic address: skhan@vikorscientific.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33070079

Citation

Ahamad, Shakir, et al. "Primed for Global Coronavirus Pandemic: Emerging Research and Clinical Outcome." European Journal of Medicinal Chemistry, vol. 209, 2021, p. 112862.
Ahamad S, Branch S, Harrelson S, et al. Primed for global coronavirus pandemic: Emerging research and clinical outcome. Eur J Med Chem. 2021;209:112862.
Ahamad, S., Branch, S., Harrelson, S., Hussain, M. K., Saquib, M., & Khan, S. (2021). Primed for global coronavirus pandemic: Emerging research and clinical outcome. European Journal of Medicinal Chemistry, 209, 112862. https://doi.org/10.1016/j.ejmech.2020.112862
Ahamad S, et al. Primed for Global Coronavirus Pandemic: Emerging Research and Clinical Outcome. Eur J Med Chem. 2021 Jan 1;209:112862. PubMed PMID: 33070079.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Primed for global coronavirus pandemic: Emerging research and clinical outcome. AU - Ahamad,Shakir, AU - Branch,Scotty, AU - Harrelson,Shea, AU - Hussain,Mohd Kamil, AU - Saquib,Mohammad, AU - Khan,Saeed, Y1 - 2020/09/19/ PY - 2020/07/08/received PY - 2020/09/17/accepted PY - 2020/10/19/pubmed PY - 2020/12/31/medline PY - 2020/10/18/entrez KW - Antiviral drugs KW - COVID-19 KW - Clinical trials KW - Drug repurposing KW - Monoclonal antibodies KW - SARS-CoV-2 KW - Small molecule drugs KW - Vaccines SP - 112862 EP - 112862 JF - European journal of medicinal chemistry JO - Eur J Med Chem VL - 209 N2 - The global effort to combat and contain the coronavirus disease 2019 (COVID-19) caused by the recently discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now proceeding on a war footing. The world was slow to react to the developing crisis, but once the contours of the impending calamity became evident, the different state and non-state actors have raced to put their act together. The COVID-19 pandemic has blatantly exposed the shortcomings of our healthcare system and the limitations of medical science, despite considerable advances in recent years. To effectively tackle the current pandemic, almost unprecedented in the modern age, there is an urgent need for a concerted, sustained, and coordinated effort towards the development of new diagnostics, therapeutic and vaccines, and the ramping up of the healthcare infrastructure, especially in the poorer underprivileged nations. Towards this end, researchers around the world are working tirelessly to develop new diagnostics, vaccines, and therapeutics. Efforts to develop a vaccine against COVID-19 are presently underway in several countries around the world, but a new vaccine is expected only by the end of the year-at the earliest. New drug development against COVID-19 and its approval may take even longer. Under such circumstances, drug repurposing has emerged as a realistic and effective strategy to counter the current menace, and several antiviral and antimalarial medicines are currently in different stages of clinical trials. Researchers are also experimenting with nutrients, vitamins, monoclonal antibodies, and convalescent plasma as immunity boosters against the SARS-CoV-2. This report presents a critical analysis of the global clinical trial landscape for COVID-19 with an emphasis on the therapeutic agents and vaccines currently being tested at pandemic speed. SN - 1768-3254 UR - https://www.unboundmedicine.com/medline/citation/33070079/Primed_for_global_coronavirus_pandemic:_Emerging_research_and_clinical_outcome_ DB - PRIME DP - Unbound Medicine ER -